T-Cell Lymphoma
T-Cell Lymphoma
The latest news, research, and perspectives in T-cell lymphoma. Most T-cell lymphomas are non-Hodgkin lymphomas that develop from mature T cells. The most common subtypes include mycosis fungoides, anaplastic large-cell lymphoma, and precursor T-lymphoblastic lymphoma.
Blood Cancers Today Staff WritersT-Cell Lymphoma | March 18, 2024
Denileukin diftitox is an IL-2-based immunotherapy for patients with relapsed or refractory CTCL.
Read More
Patrick DalyT-Cell Lymphoma | February 2, 2024
The US FDA has lifted the partial clinical hold on lacutamab following its analysis of a mortality in the TELLOMAK trial.
Patrick DalyT-Cell Lymphoma | October 17, 2023
Enrollment paused in lacutamab cutaneous and peripheral T-cell lymphoma trials after unexpected severe adverse reaction.
Swaminathan Iyer, MDVideo Insights | September 14, 2023
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Blood Cancer TalksBlood Cancer Talks | August 31, 2023
Dr. Horwitz and the hosts focus on the three most common types of PTCL and the latest research.
Cecilia BrownAggressive B-Cell Lymphoma | August 25, 2023
A first-in-human phase I trial will evaluate escalating doses of BITT2101 in patients with non-Hodgkin lymphoma.
Leah SherwoodIndolent B-Cell Lymphoma | October 15, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Cecilia BrownT-Cell Lymphoma | February 8, 2024
The regimen is under further evaluation in a randomized trial.
Leah SherwoodT-Cell Lymphoma | June 9, 2023
The proposed second phase III study comes in the wake of the recently published phase III FLASH trial.
Leah SherwoodT-Cell Lymphoma | May 11, 2023
The approval of the treatment provides patients with an alternative to a product that has historically been in shortage.
Cecilia BrownPrint | December 29, 2022
A new transcriptomic approach to the molecular classification of PTCL subtypes may have potential as a diagnostic tool.
Leah SherwoodPrint | November 23, 2022
A Biologics License Application was submitted to the FDA by the manufacturer of the drug denileukin diftitox.
Leah SherwoodT-Cell Lymphoma | November 14, 2022
The use of extracorporeal photopheresis declined in patients with Sézary syndrome as the COVID-19 pandemic began.
Kerri FitzgeraldT-Cell Lymphoma | November 14, 2022
The number of cases of cutaneous T-cell lymphoma continues to increase in the United States.
Kerri FitzgeraldT-Cell Lymphoma | November 14, 2022
There is a knowledge gap about subcutaneous panniculitis-like TCL owing to its rarity and diagnostic difficulty.
Kerri FitzgeraldT-Cell Lymphoma | November 14, 2022
Updated staging and clinical trial guidelines for primary cutaneous lymphomas (PCLs) have been proposed.
Kerri FitzgeraldPrint | November 14, 2022
Dr. Pro discusses the exciting advancements made in lymphoma and what still needs to be done to improve patient outcomes.
Cecilia BrownT-Cell Lymphoma | November 14, 2022
SGX301 is a novel, first-in-class, photodynamic therapy utilizing visible light for activation.
Leah SherwoodT-Cell Lymphoma | November 14, 2022
The single-center trial included adults with R/R multiple myeloma, T-cell lymphoma, or acute myeloid leukemia.
Leah SherwoodT-Cell Lymphoma | November 22, 2022
A pegasparaginase-based chemotherapy regimen showed promising preliminary results when compared to a regimen that was ...
Editorial Board